Zevra Therapeutics (ZVRA) Current Leases (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Current Leases data on file, last reported at $406000.0 in Q1 2026.

• Quarterly Current Leases fell 31.07% year-over-year to $406000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $406000.0 (down 31.07% YoY) and the FY2025 annual result came in at $419000.0, changed 0.24% from the prior year.
• Current Leases retreated to $406000.0 in Q1 2026, from $419000.0 in the prior quarter.
• In the past five years, Current Leases ranged from a high of $596000.0 in Q2 2024 to a low of $356000.0 in Q1 2022.
• A 5-year average of $485785.7 and a median of $475000.0 in 2022 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2022 — Current Leases soared 34.83% — and 2026, when it tumbled 31.07%.
• Tracing ZVRA's Current Leases over 5 years: stood at $480000.0 in 2022, then rose by 13.12% to $543000.0 in 2023, then declined by 22.65% to $420000.0 in 2024, then slipped by 0.24% to $419000.0 in 2025, then declined by 3.1% to $406000.0 in 2026.
• The last three Current Leases figures came in at $406000.0 (Q1 2026), $419000.0 (Q4 2025), and $441000.0 (Q3 2025), per Business Quant data.